Table 2 p503S, p504S and p510S positive cells in peripheral blood of patients with prostate cancer (CaP) in relation to Gleason score and TNM stage.
| Â | P503S+ | P504S+ | P510S+ |
|---|---|---|---|
Group 1 (treated CaP) | No | No | No |
Total (n = 11) | patients (%) | patients (%) | patients (%) |
subtype 1 without recurrence (n = 5) | 2 (40) | 2 (40) | 5 (100) |
subtype 2 with recurrence (n = 6) | 5 (83) | 5 (83) | 6 (100) |
Gleason score | Â | Â | Â |
4–7 (n = 9) | 4 (44.44) | 6 (66.66) | 9 (100) |
8 (n = 2) | 2 (100) | 2 (100) | 2 (100) |
TNM | Â | Â | Â |
Organ-confined disease (n = 7) | Â | Â | Â |
T2 N0 M0 (n = 7) | 4 (57.14) | 5 (71.42) | 7 (100) |
Extraprostatic disease (n = 4) | Â | Â | Â |
T3 N0 M0 (n = 2) | 1 (50) | 1 (50) | 2 (100) |
T3 N1M0 and T3 N2M0 (n = 2) | 2 (100) | 1 (50) | 2 (100) |
Group 2 (untreated CaP) | Â | Â | Â |
Total (n = 11) | Â | Â | Â |
Gleason score | Â | Â | Â |
6–7 (n = 11) | 2 (18.18) | 9 (81.81) | 11 (100) |
TNM | Â | Â | Â |
Organ-confined disease (n = 11) | Â | Â | Â |
T1 (n = 4) | 0 | 3 (75 | 4 (100) |
T2 (n = 7) | 2 (28.6) | 6 (85.7) | 7 (100) |